Lotus Pharmaceutical Co (美時化學製藥) has received approval from Japan’s Pharmaceuticals and Medical Devices Agency for its generic version of blood cancer drug Revlimid (lenalidomide), boosting its shares by as much as 3.54 percent in early Taipei trading yesterday.
The approval was for 2.5mg and 5mg capsules of lenalidomide, which it jointly developed with Japan’s Fuji Pharma Corp, Lotus Pharmaceutical said in a regulatory filing on Tuesday.
Lotus Pharmaceutical was responsible for developing the lenalidomide formula — the company’s first high-value generic product in Japan, while Fuji Pharma ran local bioequivalence studies of the drug.
Photo: Reuters
With the approval, Lotus Pharmaceutical is to supply the finished product to Fuji Pharma for commercialization in Japan. The companies expect to launch the product in Japan this year.
Sales of Revlimid in Japan totaled about US$282 million last year, Lotus Pharmaceutical said, citing data from life sciences researcher Iqvia Institute.
As of the second quarter, only Osaka, Japan-based Sawai Pharmaceutical Co had obtained agency approval for lenalidomide, but its generic product has not yet been marketed in the Japanese market, Lotus Pharmaceutical said.
“Lotus and Fuji are among the first to market their product in Japan and gain a good market share there,” Capital Investment Management Corp (群益投顧) said in a note yesterday. “Lotus received 16 approvals for its generic products worldwide in the second quarter, which is a remarkable achievement and will gradually contribute to its revenue and royalty income in the future.”
Lotus Pharmaceutical shares surged in early morning trading yesterday before retreating to close up 1.71 percent at NT$268.
Capital Investment gave Lotus Pharmaceutical a “buy” rating with a 12-month target price of NT$295.
Lotus Pharma’s net profit more than tripled to NT$1.27 billion (US$39.82 million) in the second quarter, up 286 percent from NT$327.67 million in the same period last year, the company said on Tuesday.
That translated into earnings per share (EPS) of NT$4.85, the best second-quarter performance in its history.
In the first half of the year, EPS totaled NT$9.43, up 217 percent year-on-year, it said.
Lotus Pharma’s cumulative revenue in the first seven months totaled NT$11.25 billion, up 58.16 percent from the same period last year, company data showed.
With better business prospects, the company projected annual revenue growth of 13 to 15 percent for this year, higher than its previous estimate of 7 to 10 percent, while gross margin is expected to reach 55 percent, compared with 50 percent in its earlier forecast.
GROWING OWINGS: While Luxembourg and China swapped the top three spots, the US continued to be the largest exposure for Taiwan for the 41st consecutive quarter The US remained the largest debtor nation to Taiwan’s banking sector for the 41st consecutive quarter at the end of September, after local banks’ exposure to the US market rose more than 2 percent from three months earlier, the central bank said. Exposure to the US increased to US$198.896 billion, up US$4.026 billion, or 2.07 percent, from US$194.87 billion in the previous quarter, data released by the central bank showed on Friday. Of the increase, about US$1.4 billion came from banks’ investments in securitized products and interbank loans in the US, while another US$2.6 billion stemmed from trust assets, including mutual funds,
AI TALENT: No financial details were released about the deal, in which top Groq executives, including its CEO, would join Nvidia to help advance the technology Nvidia Corp has agreed to a licensing deal with artificial intelligence (AI) start-up Groq, furthering its investments in companies connected to the AI boom and gaining the right to add a new type of technology to its products. The world’s largest publicly traded company has paid for the right to use Groq’s technology and is to integrate its chip design into future products. Some of the start-up’s executives are leaving to join Nvidia to help with that effort, the companies said. Groq would continue as an independent company with a new chief executive, it said on Wednesday in a post on its Web
JOINT EFFORTS: MediaTek would partner with Denso to develop custom chips to support the car-part specialist company’s driver-assist systems in an expanding market MediaTek Inc (聯發科), the world’s largest mobile phone chip designer, yesterday said it is working closely with Japan’s Denso Corp to build a custom automotive system-on-chip (SoC) solution tailored for advanced driver-assistance systems and cockpit systems, adding another customer to its new application-specific IC (ASIC) business. This effort merges Denso’s automotive-grade safety expertise and deep vehicle integration with MediaTek’s technologies cultivated through the development of Media- Tek’s Dimensity AX, leveraging efficient, high-performance SoCs and artificial intelligence (AI) capabilities to offer a scalable, production-ready platform for next-generation driver assistance, the company said in a statement yesterday. “Through this collaboration, we are bringing two
Even as the US is embarked on a bitter rivalry with China over the deployment of artificial intelligence (AI), Chinese technology is quietly making inroads into the US market. Despite considerable geopolitical tensions, Chinese open-source AI models are winning over a growing number of programmers and companies in the US. These are different from the closed generative AI models that have become household names — ChatGPT-maker OpenAI or Google’s Gemini — whose inner workings are fiercely protected. In contrast, “open” models offered by many Chinese rivals, from Alibaba (阿里巴巴) to DeepSeek (深度求索), allow programmers to customize parts of the software to suit their
RSS